[1] Maev IV, Livzan MA, Mozgovoi SI, et al. Esophageal mucosal resistance in reflux esophagitis: what we have learned so far and what remains to be learned [J]. Diagnostics (Basel), 2023, 13(16): 2664. DOI: 10.3390/diagnostics13162664.
[2] 李亦凡,朱凌云. 中西医治疗反流性食管炎临床研究进展[J]. 西部中医药,2022,35(8):153-157. DOI:10.12174/j.issn.2096-9600.2022.08.38.
[3] 宋鸿寅,薛寒冰. 幽门螺杆菌感染与反流性食管炎的相关性研究[J]. 医学综述,2016,22(24):4930-4935,4936. DOI:10.3969/j.issn.1006-2084.2016.24.039.
[4] Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance [J]. Front Cell Infect Microbiol, 2017, 7: 168. DOI: 10.3389/fcimb.2017.00168.
[5] Al-Fakhrany OM, Elekhnawy E. Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents [J]. Arch Microbiol, 2023, 205(9): 301. DOI: 10.1007/s00203-023-03639-0.
[6] Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification [J]. Gut, 1999, 45(2): 172-180. DOI: 10.1136/gut.45.2.172.
[7] Loganathan P, Gajendran M, Perisetti A, et al. Endoscopic advances in the diagnosis and management of gastroesophageal reflux disease [J]. Medicina (Kaunas), 2024, 60(7): 1120. DOI: 10.3390/medicina60071120.
[8] 刘晓红,孟宪梅. 反流性食管炎发病机制及诊断、治疗研究[J]. 中国社区医师, 2019, 35(33): 6, 8. DOI:10.3969/j.issn.1007-614x.2019.33.002.
[9] 杨竹青,郭敏,王晓鸽,等. 基于"上焦得通,津液得下,胃气因和"探讨胃食管反流病机制[J]. 北京中医药大学学报,2023,46(5):711-716. DOI:10.3969/j.issn.1006-2157. 2023.05.018.
[10] Baj J, Forma A, Sitarz M, et al. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment [J]. Cells, 2020, 10(1): 27. DOI: 10.3390/cells10010027.
[11] Ali A, AlHussaini KI. Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies [J]. Microorganisms, 2024, 12(1): 222. DOI: 10.3390/microorganisms12010222.
[12] 姜鑫,高雪峰,佘强,等. 幽门螺杆菌个体化精准根治的研究进展[J]. 国际医药卫生导报,2022,28(1):32-37. DOI:10.3760/cma.j.issn.1007-1245.2022.01.008.
[13] 张子旭,高峰,冯燕. 反流性食管炎与幽门螺杆菌感染的相关性分析[J/CD]. 中华胃食管反流病电子杂志,2015(1):28-29. DOI:10.3877/cma.j.issn.1674-6899.2015.010.09.
[14] Sugimoto M, Murata M, Mizuno H, et al. Endoscopic reflux esophagitis and reflux-related symptoms after Helicobacter pylori eradication therapy: meta-analysis [J]. J Clin Med, 2020, 9(9): 3007. DOI: 10.3390/jcm9093007.
[15] Sugimoto M, Murata M, Iwata E, et al. Risk of reflux-related symptoms and reflux esophagitis after Helicobacter pylori eradication treatment in the Japanese population [J]. J Clin Med, 2021, 10(7): 1434. DOI: 10.3390/jcm10071434.
[16] Yoshioka T, Takeshita E, Sakata Y, et al. Helicobacter pylori infection status had no influence on upper gastrointestinal symptoms: a cross-sectional analysis of 3,005 Japanese subjects without upper gastrointestinal lesions undergoing medical health checkups [J]. Esophagus, 2017, 14(3): 249-253. DOI: 10.1007/s10388-017-0573-9.
[17] 王秀琴. 抗幽门螺杆菌治疗对反流性食管炎复发率的影响[J]. 临床研究, 2019, 27(3): 84-85. DOI:10.3969/j.issn.1004-8650.2019.03.046.
[18] Chung SJ, Lim SH, Choi J, et al. Helicobacter pylori serology inversely correlated with the risk and severity of reflux esophagitis in Helicobacter pylori endemic area: a matched case-control study of 5,616 health check-up Koreans [J]. J Neurogastroenterol Motil, 2011, 17(3): 267-273. DOI: 10.5056/jnm.2011.17.3.267.
[19] Ashktorab H, Entezari O, Nouraie M, et al. Helicobacter pylori protection against reflux esophagitis [J]. Dig Dis Sci, 2012, 57(11): 2924-2928. DOI: 10.1007/s10620-012- 2349-3.
[20] 伍蓓. 初探幽门螺杆菌感染与反流性食管炎的相关性[J]. 生物医学工程学进展,2016,37(3):141-143. DOI:10.3969/j.issn.1674-1242.2016.03.006.
[21] 雷婷婷,陈玲. 反流性食管炎与幽门螺杆菌感染相关性的Meta分析[J]. 现代预防医学,2020,47(13):2480-2486.
[22] 王秀琴. 抗幽门螺杆菌治疗对反流性食管炎复发率的影响[J].临床研究, 2019, 27(3): 84 - 85. DOI: 10.3969/j.issn. 1004-8650.2019.03.046.
[23] 熊德山,王用兵. Hp感染与反流性食管炎发病的关系及根除Hp治疗对患者预后的影响[J]. 贵州医药,2018,42(6):696-698. DOI:10.3969/j.issn.1000-744X.2018.06.023.
[24] 薛正青. 幽门螺杆菌感染与反流性食管炎之间的关系分析[J]. 医学食疗与健康,2019(23):64-65.
|